Therapeutic responses to different anti-Trypanosoma cruzidrugs in experimental infection by benznidazole-resistant parasite stock
- 21 July 2014
- journal article
- research article
- Published by Cambridge University Press (CUP) in Parasitology
- Vol. 141 (12), 1628-1637
- https://doi.org/10.1017/s0031182014000882
Abstract
This study describes the role of parasite clearance time induced by benznidazole, fexinidazole and posaconazole treatments upon mice infection with a benznidazole-resistant Trypanosoma cruzi strain in the pathological outcomes. Trypanosoma cruzi-infected mice were treated with different drugs and parasite clearance time was detected by blood and tissue qPCR, to determine the dynamic relationship between the efficacy of the treatments and the intensity of heart lesion/serum inflammatory mediators. Our results indicate that anti-T. cruzi treatments were able to reduce parasite replication and consequently induce immunomodulatory effects, where the degree of the immunopathology prevention was related to the time of parasite clearance induced by different treatments. Nevertheless, in benznidazole and posaconazole treatments, parasite rebounding was detected with parasitism reaching levels similar to infected and non-treated mice; the time for parasitic rebound being earlier among benznidazole-treated mice. In parallel, an increase of cardiac lesions and plasma chemokine levels was also detected and was more accentuated in benznidazole-treated animals. Interestingly, in the presence of parasitological cure (fexinidazole treatment), basal levels of these inflammatory mediators were evidenced as well as an absence of cardiac inflammation or fibrosis. Overall, our data indicate that all treatments have positive effects on the clinical evolution of T. cruzi infection, with success in preventing cardiac alterations being drug-dependent.Keywords
This publication has 30 references indexed in Scilit:
- Benznidazole and Posaconazole in Experimental Chagas Disease: Positive Interaction in Concomitant and Sequential TreatmentsPLoS Neglected Tropical Diseases, 2013
- Fexinidazole: A Potential New Drug Candidate for Chagas DiseasePLoS Neglected Tropical Diseases, 2012
- Activation of Benznidazole by Trypanosomal Type I Nitroreductases Results in Glyoxal FormationAntimicrobial Agents and Chemotherapy, 2012
- Fexinidazole – A New Oral Nitroimidazole Drug Candidate Entering Clinical Development for the Treatment of Sleeping SicknessPLoS Neglected Tropical Diseases, 2010
- Effects of Ravuconazole Treatment on Parasite Load and Immune Response in Dogs Experimentally Infected with Trypanosoma cruziAntimicrobial Agents and Chemotherapy, 2010
- Cross-Resistance to Nitro Drugs and Implications for Treatment of Human African TrypanosomiasisAntimicrobial Agents and Chemotherapy, 2010
- Successful Treatment with Posaconazole of a Patient with Chronic Chagas Disease and Systemic Lupus ErythematosusThe American Journal of Tropical Medicine and Hygiene, 2010
- Nitric oxide synthase-2 modulates chemokine production by Trypanosoma cruzi-infected cardiac myocytesMicrobes and Infection, 2008
- Benznidazole therapy during acute phase of Chagas disease reduces parasite load but does not prevent chronic cardiac lesionsZeitschrift für Parasitenkunde, 2008
- Chagas Disease Etiology: Autoimmunity or Parasite Persistence?Parasitology Today, 1999